Nuvo Pharmaceuticals Inc NRIFF

RE:Earnings Conference Call

[consultant99]

Problem has apparently been fixed and the webcast is available now.

After listening to the call I am more confused than ever by talk of potentially focusing on Pennsaid 1.5% approval in other regions and the the use of a "foam" application to extend patent protection. This came up in response to a question and the answer was devoid of clarity and substance. 

It seems obvious that the average shareholder is not in the loop when it comes to future developments even after reading the quarterly management notes.

If I take JL's answer to the first question on what is the likely revenue stream in future quarters going to look like at face value - Nuvo hasn't a clue. I take that to mean they do not have a collaborative partnership relationship with Horizon - as John noted Horizon treats us like a contract manufacturer. They are afraid to make any disclosures not already in the public domain.
 
One other point not related to the call is that the stock has been lingering at 52 week lows but suddenly perked up prior to the earnings report. Clearly the market believes that the report was a positive and the stock continues higher today. Simply based on these observations it suggests that information could have been leaked. 

I wonder if any shareholders/investors knew before the earnings release about the plant supplying Horizon non-seralized product in Q3.

Regardless it begs the question as to why the company would not have sent out a PR in as this is surely a material change to expected earnings in Q3.